Hemab Therapeutics Q3 net loss widens to $27.3 million; cash totals $430.2 million
Hemab Therapeutics reported a third-quarter 2026 net loss of $27.3 million, up from $17.1 million a year earlier, as research and development and general and administrative expenses rose. Net loss per share improved to $0.58 from $18.04, but the company attributes that change mainly to a larger weighted-average share count after its initial public offering and preferred stock conversion. The company said its cash, cash equivalents and marketable securities of $430.2 million will fund operations into 2029, and it started the Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia.
Key points
- Net loss was $27.3 million, or $0.58 per share, for the quarter ended September 30, 2026, versus $17.1 million, or $18.04 per share, a year earlier
- Research and development expenses were $24.6 million, up from $14.6 million; general and administrative expenses were $5.1 million, up from $2.5 million
- Cash, cash equivalents and marketable securities were $430.2 million at September 30, 2026, versus $457.5 million at June 30, 2026, with runway stated as into 2029
- Phase 3 SOLARA trial of sutacimig in Glanzmann thrombasthenia was initiated, with first participants scheduled to enter the run-in period in the fourth quarter of 2026
The filing
Written by AI on Nov 10, 2026, 7:16 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.